Key Takeaways
- •Medicare spends billions of dollars each year managing the downstream consequences of obesity, including type 2 diabetes, cardiovascular disease, and joint replacements.
- •According to the Centers for Medicare and Medicaid Services, obesity-related conditions account for a significant portion of Medicare expenditures.
- •In a recent press release, Ascletis Pharma announced that its once-monthly subcutaneously administered GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, demonstrated superior weight loss in a diet-induced obese mouse model.
Medicare spends billions of dollars each year managing the downstream consequences of obesity, including type 2 diabetes, cardiovascular disease, and joint replacements. Yet the program does not cover GLP-1 receptor agonists for weight loss when prescribed solely for obesity. This policy gap has become a central point of debate as new peptide-based therapies continue to show promise in clinical research.
The Cost of Obesity to Medicare
According to the Centers for Medicare and Medicaid Services, obesity-related conditions account for a significant portion of Medicare expenditures. The program pays for hospitalizations, surgeries, and long-term management of diseases linked to excess weight. Early reports suggest that covering GLP-1 drugs for weight loss could reduce these downstream costs, but the upfront price of these medications remains a barrier.
Ascletis Announces ASC37: A Triple Peptide Agonist
In a recent press release, Ascletis Pharma announced that its once-monthly subcutaneously administered GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, demonstrated superior weight loss in a diet-induced obese mouse model. This development is part of a broader trend in peptide research toward multi-receptor agonists that may offer enhanced efficacy and dosing convenience.
ASC37 targets three receptors: GLP-1, GIP, and glucagon. By activating these pathways simultaneously, the peptide aims to improve weight loss outcomes beyond what single or dual agonists can achieve. The once-monthly dosing schedule could also improve patient adherence, a key challenge in obesity management.
Implications for Medicare and Peptide Research
If ASC37 or similar peptides advance to human trials and eventually receive regulatory approval from the FDA, they could reshape the conversation around Medicare coverage. The agency has reportedly been cautious about covering weight loss drugs due to cost concerns. However, if triple agonists demonstrate superior efficacy and safety, the cost-benefit analysis may shift.
For researchers and industry professionals, this news highlights the rapid evolution of peptide therapeutics. Tools like the Peptide Glossary can help clarify the mechanisms of these complex molecules. Additionally, the Dosage and Cycle Planner-cycle-planner) is useful for planning preclinical studies.
Ozempic News and the Broader GLP-1 Landscape
Ozempic news often dominates headlines, but the peptide industry is moving beyond single-receptor agonists. While Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight loss, newer candidates like ASC37 aim to offer more comprehensive metabolic benefits. The FDA has not yet approved any triple agonist for clinical use, but the preclinical data from Ascletis is encouraging.
What This Means for Researchers
For peptide researchers, the development of ASC37 underscores the importance of multi-target strategies. The ability to activate GLP-1, GIP, and glucagon receptors simultaneously may lead to better weight loss and glycemic control. Researchers can use the Reconstitution Calculator-calculator) to prepare accurate doses for animal studies.
Related Research Compounds
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg | ≥98% | 10mg | $49.00 |
FAQ
What is Ozempic?
Ozempic is a brand name for semaglutide, a GLP-1 receptor agonist used to treat type 2 diabetes and, in higher doses, for weight management. It is administered once weekly by subcutaneous injection.
Is Ozempic safe?
Ozempic is approved by the FDA for its indicated uses. Common side effects include nausea, vomiting, and diarrhea. Serious side effects may include pancreatitis and thyroid tumors. Patients should consult their healthcare provider for personalized advice.
What are the side effects of Ozempic?
Reported side effects of Ozempic include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. Less common but serious side effects may include pancreatitis, gallbladder disease, and kidney injury. Early reports suggest that these side effects are generally manageable but require medical supervision.